Abstract 297P
Background
Radiotherapy and chemotherapy, or a combination of both have a significant role in the management of cervical cancer. In order to reduce the burden of cervical cancer in a tangible way especially in Indonesia, the need for both modalities demand must be assessed. Considering this, it is necessary to discuss and determine the calculation of the optimal and actual Radiotherapy and Chemotherapy Utilization Rate (RUR and CUR), also the unmet need (gap) between the two rates for cervical cancer in Indonesia.
Methods
Descriptive study of cross-sectional design, total sampling method by taking secondary data from cancer registries and/or internal medical records of participating hospitals with radiotherapy centres in Indonesia in 2019. Data were then separated into hospital data (all cervical cancer cases in the hospital) and RT data (cases from radiotherapy department only).
Results
The total data from the 33 participating hospitals was 4937, divided into 3617 hospital data and 1320 RT data.
The average age of patients was 48-52 years (7-91 years). Patient domicile was mostly from Java Island. Stage III was the most common stage (39.4%). Cervical cancer management was dominated by radiotherapy alone and chemoradiation (28.5% and 27.4%).
Optimal rates can only be based on hospital data that have complete stage attributes.
The optimal, actual RUR and unmet need values were 97.2% (90.9-97.4%), 61.24%, and 36.7% (32.62-37.13%), respectively.
For CUR, the optimal, actual and unmet need values were 87.8% (81-88%), 40%, 54.5% (50.8-55%), respectively.
The actual RUR and CUR for combined data were 70.93% and 39.6%, respectively.
Conclusions
The optimal and actual values of RUR and CUR for cervical cancer in Indonesia still have a large gap, indicating more need for demand of both modalities.
Efforts are needed to increase the actualization of RUR and CUR closer to their optimal rate. Factors affecting RUR and CUR should be explored universally including the patient, clinician, and healthcare system aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract